"Our price target is based on what we consider to be a fair multiple, parity with the group 2013E multiple of 12.7x applied to 2013E PFE earnings of $2.26. Our target price is based on our 3D valuation framework. Pfizer scores below average on its 2012E-2016E pipeline and has the least patent exposure and a slightly below-average score on company-specific factors," said analyst Jon LeCroy, M.D.

For an analyst ratings summary and ratings history on Pfizer click here. For more ratings news on Pfizer click here.